"Hot" Research Areas in Drug Discovery - 2019

   by Andrii Buvailo    8702    Comments 0

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

Topics: Industry Trends   

Things like gene editing, stem cells, immunotherapies and new types of biologics are now mega-trends in the pharmaceutical industry, widely covered in media, and I guess there is little doubt that biology is the next big thing in medicine. However, in this post I would like to outline several hot areas in small molecule drug discovery, suggesting a lot of untapped potential and investment prospects in this more “traditional” pharmaceutical research space.

 

1.Targeting ribonucleic acid (RNA)

 

The majority of existing marketed drugs out there are designed to somehow modulate proteins in the body, thereby disrupting a disease progression. However, going one step back and trying to disrupt a pathological process earlier --  right before a protein is actually made in the body -- seems a powerful concept. This can be achieved by influencing ribonucleic acid (RNA), a central actor molecule in the process of gene expression -- the one leading to formation of proteins as instructed by human genome.

 

Epitranscriptomics

 

One rapidly growing strategy to deal with RNA involves targeting natural enzymes and proteins that are responsible for its chemical modifications (for example, methylation or de-methylation). The interest to this idea was ignited by a Rupert Fray’s study in May 2008 showing the essential role of RNA methyl-adding enzymes in plant development. In just several years it has become a whole new area of science, called “epitranscriptomics” (a term coined in 2012 by Samie Jaffrey), and the key players here include three biotech startups: Accent Therapeutics, launched with $40 million in May 2018, Gotham Therapeutics, launched with $54 million in October 2018, and Storm Therapeutics being in the process of raising approximately $65 million for its second round of cash from investors. All three startups are focusing on developing novel small molecules to inhibit RNA-modifying enzymes. There is a wonderful review about epitranscriptomics and its short history in C&EN.

 

Targeting RNA with small molecules

 

BiopharmaTrend Premium

This content is available to our premium users.

Get the following benefits by becoming premium member:

  • - unlock premium articles
  • - get access to our industry reports
  • - support our independent media

 Join Now 

Already a member?

Topics: Industry Trends   

Share this:              

You may also be interested to read:

 

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *